Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Thomas

Adult Medicine Virginia Beach, VA Medical Doctor

NPI 1922074079 CMS profile 269191

1821 Old Donation Pkwy, Suite 4, Virginia Beach, VA 23454

Open in the dashboard

General payments

$7,554

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Thomas of Virginia Beach, VA is reported in the CMS Open Payments database as having received $7,554 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125 1
2024 General $560 5
2023 General $891 8
2022 General $1,366 13
2021 General $1,500 15
2020 General $381 13
2019 General $2,731 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Thomas
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Laura Thomas were reported at $125. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Laura Thomas Adult Medicine median Middle half National median
2019 $2,731 $140 $41–$517 $163
2020 $381 $107 $25–$378 $114
2021 $1,500 $136 $32–$529 $132
2022 $1,366 $138 $39–$492 $149
2023 $891 $155 $46–$483 $160
2024 $560 $153 $46–$554 $164
2025 $125 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,048 14 payments
  2. AstraZeneca Pharmaceuticals LP $822 17 payments
  3. Sanofi-Aventis U.S. LLC $756 7 payments
  4. Janssen Pharmaceuticals, Inc $680 13 payments
  5. Lilly USA, LLC $639 16 payments
  6. Novo Nordisk Inc $533 8 payments
  7. Astellas Pharma US Inc $462 4 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $362 3 payments
  9. Amarin Pharma Inc. $279 5 payments
  10. GlaxoSmithKline, LLC. $247 3 payments
  11. Other $1,725 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,448 116 payments
  2. Education $106 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $705 13 payments
  2. XARELTO $680 13 payments
  3. Saxenda $385 5 payments
  4. Kerendia $362 3 payments
  5. MOUNJARO $348 3 payments
  6. EVENITY $330 5 payments
  7. Repatha $283 5 payments
  8. TRELEGY ELLIPTA $238 2 payments
  9. MYRBETRIQ $237 2 payments
  10. AIMOVIG $235 4 payments
  11. Other $3,473 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

241

Median for Family Practice: 1,826

Drug cost

$17,225

Median for Family Practice: $120,094

Branded share of claims

9.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 11 $11,915
Acetylcysteine Generic 17 $2,086
Ventolin Hfa Albuterol Sulfate Brand 12 $669
Metoprolol Succinate Generic 29 $583
Rosuvastatin Calcium Generic 30 $407
Atorvastatin Calcium Generic 34 $339
Duloxetine Hcl Generic 12 $281
Amlodipine Besylate Generic 23 $259
Levothyroxine Sodium Generic 13 $192
Sertraline Hcl Generic 15 $180

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $125
$125 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $113
$113 — —
EVENITY
  • Amgen Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record